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INTRODUCTION
In the treatment of locally advanced rectal cancer (LARC),
the possible advantages of preoperative treatment compared
with upfront surgery include lower toxicity, increased resec-
tability, and an increased rate of sphincter preservation. A re-
cently published phase III study in Germany showed impro-
ved pelvic control and sphincter preservation and less acute/
chronic toxicity with preoperative chemoradiation than with
postoperative chemoradiation (1). Although a randomised
trial comparing chemoradiation to radiotherapy alone in the
preoperative setting is not yet complete, the rationale for using
concurrent chemotherapy is based on extrapolation from phase
III postoperative trials (2, 3).
Regimens of 5-FU/leucovorin (LV) have been considered
the standard therapy for patients with advanced colorectal
cancer (4, 5). The LV-modulated intravenous (i.v.) bolus regi-
men is widely used because of its convenience and document-
ed efficacy compared with bolus 5-FU alone (6). Comparing
the efficacy of the two infusion methods, bolus vs. continu-
ous infusion (CI) of 5-FU, CI is superior to bolus infusion in
terms of tumor response and is associated with a slight increa-
se in the overall survival of patients with advanced colorectal
cancer (7). While CI has the biological advantage of prolong-
ing the exposure of cells to 5-FU and improving anti-tumor
activity, its disadvantages include the need for indwelling ca-
theters and infusion pumps, with potential complications,
such as infection, bleeding, thrombosis, and pneumothorax,
which can result from central venous access (4).
Orally administered fluoropyrimidines were developed to
prolong the anti-tumor activity of 5-FU. These drugs mimic
the pharmacokinetics of CI 5-FU but avoid the technical bar-
riers of i.v. infusion. In a questionnaire-based study, most pa-
tients preferred oral chemotherapy to i.v. infusion with respect
to the quality of life, as long as the therapeutic effects were
equivalent (8).
Capecitabine (Xeloda, Roche, Seoul, Korea) is a new oral
fluoropyrimidine carbamate that was rationally designed to
be converted to 5-FU, preferentially within tumor cells, via
three sequential enzymatic steps. The enzyme thymidine pho-
sphorylase converts 5′ -deoxy-5-fluorouridine to 5-FU at the
final step. In colorectal cancers, the level of thymidine phos-
phorylase is significantly higher in tumor tissue than in adja-
cent normal tissue or plasma. This results in the tumor-selec-
tive generation of 5-FU (9). In addition, radiotherapy can up-
regulate thymidine phosphorylase in tumor cells but not in
normal tissue (10). Thus, there may be a synergistic effect bet-
ween radiotherapy and capecitabine.







Department of Radiation Oncology, College of
Medicine, Seoul National University, Seoul; 
Departments of Radiation Oncology*, General 
Surgery
� , Pathology
� , Cancer Research Institute
�,




Department of Radiation Oncology, Chungnam
National University Hospital, 640 Daesa-dong, 
Jung-gu, Daejeon 301-721, Korea
Tel : +82.42-259-8108, Fax : +82.42-220-7899
E-mail : k423j@cnu.ac.kr
52
J Korean Med Sci 2006; 21: 52-7
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Comparison of the Efficacy of Oral Capecitabine versus Bolus 5-FU
in Preoperative Radiotherapy of Locally Advanced Rectal Cancer
The effects of treatment with oral capecitabine vs. bolus 5-FU, administered concur-
rently with preoperative radiotherapy, were compared in the treatment of locally ad-
vanced rectal cancer (LARC). One hundred and twenty-seven patients with LARC
received concurrent preoperative chemoradiation using two cycles bolus 5-FU (500
mg/m
2/day) plus leucovorin (LV, 20 mg/m
2/day) (Group I). Another LARC group re-
ceived concurrent chemoradiation using two cycles 1,650 mg/m
2/day of oral capeci-
tabine and 20 mg/m
2/day of LV (Group II, 97 patients). Radiation was delivered to
the primary tumor at 50.4 Gy in both groups. Definitive surgery was performed 6
weeks after the completion of chemoradiation. A pathologic complete remission was
achieved in 11.4% of patients in Group I and in 22.2% of patients in Group II (p=
0.042). The down-staging rates of the primary tumor and lymph nodes were 39.0/
68.7% in Group I and 61.1/87.5% in Group II (p=0.002/0.005). Sphincter-preserv-
ing surgery was possible in 42.1% of patients in Group I and 66.7% of those in Group
II (p=0.021). Grade 3 or 4 leucopenia, diarrhea, and radiation dermatitis were sta-
tistically more prevalent in Group I than in Group II, while the opposite was true for
grade 3 hand-foot syndrome. Preoperative chemoradiation using oral capecitabine
was better tolerated than bolus 5-FU and was more effective in the promotion of
both down-staging and sphincter preservation in patients with LARC.
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There has been no study comparing the efficacy of bolus
5-FU with the newly developed oral chemotherapeutic agent,
capecitabine in the preoperative chemoradiotherapy of pa-
tients with rectal cancer. Beginning in 1993, however, we
instituted a consistent treatment policy of preoperative che-
moradiotherapy for patients with LARC. This policy com-
prised two different chemotherapeutic regimens: bolus 5-FU/
LV and oral capecitabine/LV. The current study is aimed at
retrospectively comparing the efficacies of these two regimens
(including the degree of tumor down-staging and contribu-
tion to sphincter-preserving surgery) as well as their toxici-
ties to patients in the preoperative chemoradiation therapy
of LARC.
MATERIALS AND METHODS
Since July 1993, patients with LARC were enrolled for
preoperative chemoradiotherapy at Chungnam National Uni-
versity Hospital. The eligibility criteria were as follows: histo-
logical proof of rectal adenocarcinoma, tumor extension thro-
ugh the bowel wall (T3-T4) or pelvic lymph-node involve-
ment without evidence of distant metastasis (as determined
by clinical work-ups, including computed tomography), and
a resectable or potentially resectable tumor. The pre-treatment
clinical TNM stage was mainly determined by computed to-
mography (CT) imaging. Therefore, the pre-treatment TNM
staging of the patients’ tumors was carefully defined based
on a joint review of CT images by a radiation oncologist, a
surgeon, and a diagnostic radiologist. The TNM stages were
reclassified according to the 5th edition of American Joint
Committee on Cancer (AJCC) cancer staging manual. In gen-
eral, the clinical T and N stages were determined by digital
rectal examination and pelvic CT scans. Tumors were deemed
T4 if there was evidence of invasion of neighboring organs,
or T3 if palpation revealed the tumor to be partially or totally
fixed, or if CT scanning showed tumor extension into the peri-
rectal fat tissue. The lymph node involvement was regarded
as positive when size of the adjacent perirectal lymph node
was ≥3 mm or that of the other pelvic lymph node was ≥10
mm. Essential pre-treatment work-ups included a complete
history, digital rectal examination, complete blood count, se-
rum chemistry, CEA level, chest radiography, abdominal/
pelvic CT scan, and colonoscopy with biopsy. Informed con-
sent was obtained from all patients.
Between July 1993 and June 1999, 127 patients with
LARC received two cycles of i.v. bolus 5-FU (500 mg/m
2/day)
and LV (20 mg/m
2/day) for 5 days each. Each cycle of chemo-
therapy was administered concurrently in an outpatient set-
ting on the first and fifth weeks of pelvic preoperative radio-
therapy. These patients formed Group I (bolus-5-FU/LV-treat-
ed patients). Ninety-seven additional patients were registered
from July 1999 to July 2002, at the time when the chemo-
therapy regimen had changed from i.v. 5-FU/LV to oral chemo-
therapy consisting of two cycles of capecitabine and LV. Ca-
pecitabine was given orally to these patients at a dose of 1,650
mg/m
2/day, which was divided into two doses given 12 hr
apart. LV (20 mg/m
2/day) was also divided into two doses. In
both group, LV was used to enhance of 5-FU activity. Patients
were advised to take the oral chemotherapeutics after break-
fast and dinner. One cycle of oral chemotherapy was contin-
ued for 14 days and was followed by a 7-day rest period. These
patients formed Group II (oral capecitabine/LV-treated pa-
tients). The dose and administration schedule of capecitabine
was based on results of the studies of Mackean et al. and Cas-
sidy et al. (11, 12). 
The characteristics of the patients enrolled in Groups I and
II were analysed (Table 1). There was no significant difference
between the two groups with respect to sex, age, and ECOG
performance status. Regarding tumor mobility, Group II pa-
tients had more clinically fixed tumors than did patients in
Group I, as determined by an initial digital rectal examina-
tion. The clinical stages of the tumors and lymph nodes were
comparable in the two groups. The mean tumor size mea-
sured in the longest dimension by colonoscopy and/or CT
imaging did not differ statistically between the groups. The
mean distance of the tumor from the anal verge (clinically
measured at the time of enrolment) was shorter in Group I
patients than in Group II patients (5.0 vs. 5.7 cm). However
there was no statistical difference between the two groups
when only those patients who received surgery were analysed.
AV, Anal verge; *ECOG performance scale; 
� AJCC 5th edition, 1997.
Group I (n=127) Group II (n=97) p-value
Sex (male:female) 81:46 61:36 0.89
Age (yr) (median) 25-79 (57) 30-80 (59) 0.58
Size (cm, mean±SD) 4.8±1.7 4.4±1.6 0.06
≤4 60 (47%) 54 (56%)
>4 67 (53%) 43 (44%)
Distance from AV 5.0±2.2 5.7±2.3 0.02
(cm, mean±SD)
≤5 76 (60%) 41 (42%)
>5 51 (40%) 56 (58%)
Performance status* 0.54
0 3 (2.8%) 1 (1.1%)
1 114 (90.5%) 91 (95.6%)
2 10 (6.7%) 5 (3.3%)
Tumor mobility 0.05
Mobile 16 (13.3%) 13 (12.2%)
Partially fixed 72 (56.2%) 39 (38.9%)
Totally fixed 37 (28.6%) 42 (45.6%)
Unknown 2 (1.9%) 3 (3.3%)
Clinical stage
� 0.48
T3 N0 M0 27 (21.2%) 22 (22.7%) 
T3 N1 M0 35 (27.6%) 31 (32.0%)
T2 N2 M0 0 (0%) 1 (1.0%)
T3 N2 M0 57 (44.9%) 33 (34.0%)
T4 N1 M0 2 (1.6%) 3 (3.1%) 
T4 N2 M0 6 (4.7%) 7 (7.2%)
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Throughout the 9-yr period that was studied, the radiation
therapy technique administered to patients enrolled in the
two groups was identical. Radiation was delivered with 6-
and 10-MV photons using a three-field technique (posterior
and both laterals) in most patients. Treatment was planned
using computerised dosimetry, and a dose of 1.8 Gy per frac-
tion was prescribed to cover the planning target volume with
the 95% reference isodose (95% of the ICRU point dose). Pa-
tients were treated in the prone position and were encouraged
to have a full bladder during irradiation. No devices were used
to displace the small bowel from the treatment field, and sha-
ped blocks were used to exclude normal tissues. Radiothera-
py was delivered 5 days per week, once per day, at 1.8 Gy per
day. The whole pelvis received 45 Gy in 25 fractions over 5
weeks; this was followed by a boost dose of 5.4 Gy adminis-
tered in three fractions to the primary tumor by two lateral
fields. For the whole-pelvis field, the superior border was at
the L5-S1 interspace, and the inferior border was 3-4 cm bel-
ow the primary tumor. The lateral border was 1.5 cm outside
the true bony pelvis. For the lateral fields, the posterior mar-
gin was 1.5 cm behind the anterior bony sacral margin, and
anterior border was usually anterior or midacetabulum. 
During the course of radiation therapy, patients were eval-
uated and interviewed weekly with radiation oncologist in
order to not only assess acute toxicity and compliance with
the chemoradiation but also to verify that oral capecitabine
was taken properly. Acute toxicity was assessed according to
the NCI common toxicity criteria (13). Four weeks after the
completion of chemoradiation, tumor-restaging procedures
were performed that included physical examination, comple-
te blood count, serum chemistry, CEA level, chest radiogra-
phy, and abdominal/pelvic CT scan. Approximately 6 weeks
after completion of the chemoradiation, patients underwent
definitive surgery. Surgical management included a sphinc-
ter-preservation approach whenever possible, using the total
mesorectal excision technique. Pathological evaluation of the
surgical specimens, including the primary tumor and the re-
moved nodes, was performed based on the tumor regression
grade according to the criteria proposed by Mandard et al. for
esophageal carcinomas treated with chemoradiotherapy (14).
Only the cases showing the complete absence of residual tu-
mor cells were designated as being in pathologic complete
remission (pCR). In order to evaluate the effect of preopera-
tive chemoradiation on tumor down-staging, the pre-treat-
ment clinical TNM stage was compared with the postopera-
tive pathological TNM stage. Primary tumor and node down-
staging were defined as reductions in T and N stages by at
least one level.
The patients’ characteristics, hematologic/non-hematologic
toxicities, down-staging, sphincter preservation, and postop-
erative complications were compared across the two groups
using the chi-square test, Fisher’s exact test, or the t-test when
appropriate. p values of less than 0.05 were considered to be
statistically significant. All statistical analyses were conducted
using the SPSS (Version 10.0) statistical software program
(SPSS, Chicago, IL, U.S.A.).
RESULTS
Among the 127 patients in Group I, treated with bolus 5-
FU/LV, six had a modification of the chemotherapy scheme
during the course of treatment: the second course was skipped
in four patients and the dose was reduced in two patients
because of toxicity. Only one of the 97 patients in Group II
skipped the second course of oral chemotherapy, because of
grade 2 nausea/vomiting along with the patient’s refusal. After
completing preoperative chemoradiation, 105 (82.7%) of the
127 patients in Group I and 90 (92.8%) of the 97 patients
in Group II underwent definitive surgery. Twenty-two pa-
tients in Group I and seven patients in Group II refused de-
finitive surgery following chemoradiation therapy. The desire
for the preservation of a functional anus accounted for a con-
siderable portion of the reasons expressed by these patients
(14/22 in Group I, 5/7 in Group II). Two patients in Group
I refused surgery; one experienced grade 3 diarrhea and leu-
copenia during chemoradiation, and the other experienced
colitis after chemoradiation. The types and numbers of sur-
gical resections performed in Groups I/II were: low anterior
resection, 62/57; abdominoperineal resection, 28/11; colo-anal
reconstruction, 5/18; Hartmann procedure, 4/2; total proc-
tocolectomy, 6/0; and trans-anal full-thickness excision, 0/2.
Tumor response and down-staging
Postoperative pathologic stages were evaluated in patients
who underwent definitive surgery (Table 2). The pathologic
stage of tumors in the patients of Groups I/II were as follows:
pCR (T0N0) in 11.4/22.2%; stage I (T1-2N0) in 20.0/22.2%;
stage II (T3-4N0) in 27.6/31.2%; stage III (any T, N1-2) in
31.5/21.1%; and stage IV (any T, any N, M1) in 9.5/3.3%.
The overall distributions of postoperative pathological stages
between Group I and Group II showed only marginal statis-
tical difference (p=0.076). Especially with respect to pCR fol-
lowing preoperative chemoradiation, Group II patients had
a higher pCR rate than Group I patients (p=0.042).
Postoperative pathological stages were analysed in both
groups and was compared with pre-treatment clinical stages.
Primary tumor and node down-staging were achieved in 39.0/
61.1% and 68.7/87.5% of the patients in Groups I/II, respec-
tively (Table 3). The overall down-staging rate, including pri-
mary tumor and node down-staging in Group I/II patients,
was 70.5/86.7%. Group II patients had a higher overall down-
staging rate than patients in Group I (p=0.007).
Sphincter preservation 
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of the 195 patients. Sphincter preservation was analysed in
patients with distal rectal tumors, defined as those initially
located 5 cm or less from the anal verge (Table 3). Fifty-seven
(54.3%) of 105 patients in Group I and 36 (40%) of 90 pa-
tients in Group II had tumors located 5 cm or less from the
anal verge on initial enrolment. The postoperative sphincter-
preservation rates of patients with distal rectal tumors were
24/57 (42.1%) in Group I and 24/36 (66.7%) in Group II
(p=0.021). 
Toxicity during preoperative chemoradiation
The incidences of acute toxicities during chemoradiation
in Groups I and II are listed in Table 4. With respect to grade
3 or 4 hematologic toxicity, ten patients in Group I had grade
3 (in 8) or grade 4 (in 2) leucopenia, but none of the patients
in Group II had grade 3 or 4 leucopenia (p=0.005). Among
Group I patients, one had grade 3 and another had grade 4
thrombocytopenia, whereas no thrombocytopenia of grade 3
or 4 developed in Group II. Regarding non-hematologic to-
xicities, no grade 4 toxicities were noted in either group. The
most common grade 3 non-hematologic toxicity in Group I
patients was diarrhea (22.8%), followed by radiation derma-
titis (11.8%) and fatigue (5.5%). Group II patients had the
following grade 3 non-hematologic toxicities: diarrhea (11.3
%), hand-foot syndrome (6.2%), and fatigue (5.2%). Grade
3 diarrhea and radiation dermatitis were more prevalent in
Group I, but grade 3 hand-foot syndrome occurred more fre-
quently in Group II (p=0.005). There were no life-threaten-
ing complications associated with either of the chemoradia-
tion regimens and no postoperative deaths.
Postoperative complications
Postoperative complications occurring within 3 months
after surgery were evaluated. In Group I patients, postoper-
ative complications requiring conservative management were
delayed wound healing over 4 weeks in four, intestinal obst-
ruction in four, neurogenic bladder in one, and pelvic abscess
in one. Three complications required surgical management
in Group I patients: intestinal obstruction in one, anastomo-
sis leakage in one, and pelvic abscess in one. In Group II pa-
tients, postoperative complications requiring conservative
management were delayed wound healing in one, intestinal
obstruction in six, ureter stenosis in one, neurogenic bladder
in one, and pelvic abscess in two. Complications requiring
surgical management in Group II patients were anastomosis
leakage in one, pelvic abscess in one, and rectovaginal fistu-
la in one. There was no statistical difference in the rate of post-
operative complications between the patients in Group I
(12.4%) and Group II (15.5%) (p=0.81).
DISCUSSION
Over the past decade, several groups have reported the effects
CR, complete remission; *AJCC 5th edition, 1997; 
� p-value between Group
I and Group II was 0.042.
AJCC stage* Group I (n=105) Group II (n=90) p-value
Pathologic CR 12 (11.4%)
� 20 (22.2%)
�
I 21 (20.0%) 20 (22.2%)
T1 N0 M0 3  1
T2 N0 M0 18  19
II 29 (27.6%) 28 (31.2%)
T3 N0 M0 29 28
III 33 (31.5%) 19 (21.1%) 0.076
T0 N1 M0 0 4
T2 N1 M0 2 4
T3 N1 M0 18 6
T4 N1 M0 3 1
T2 N2 M0 2 1 
T3 N2 M0 8 1
T4 N2 M0 0 2
IV 10 ( 9.5%) 3 (3.3%)
T1 N0 M1 0 1
T2 N0 M1 0 1
T3 N1 M1 4 1
T3 N2 M1 5 0 
T4 N2 M1 1 0
Table 2. Postoperative pathologic stage distribution
*Tumors initially located within 5 cm from anal verge on pretreatment
digital rectal examination.
Group I (n=105) Group II (n=90) p-value
Down-staging
T stage 41/105 (39.0%) 55/90 (61.1%) 0.002
N stage 57/ 83 (68.7%) 63/72 (87.5%) 0.005
Overall down-staging 74/105 (70.5%) 78/90 (86.7%) 0.007
Sphincter preservation* 24/57 (42.1%) 24/36 (66.7%) 0.021
Table 3. Down-staging by comparing pretreatment clinical stage
with postoperative pathologic stage and sphincter preservation
n.s., not significant.
Group I (n=127) Group II (n=97) p-value
Hematologic 
Anemia 0 0 n.s.
Leucopenia 10 (7.9%) 0 0.005
Thrombocytopenia 2 (1.6%) 0 n.s.
Nonhematologic
Fatigue 7 (5.5%) 5 (5.2%) n.s.
Anorexia 2 (1.6%) 1 (1.0%) n.s.
Nausea 1 (0.8%) 0 n.s.
Vomiting 0 0 n.s.
Diarrhea 29 (22.8%) 1 (11.3%) 0.026
Stomatitis 0 0 n.s. 
Radiation dermatitis 15 (11.8%) 3 (3.1%) 0.018
Hand-foot syndrome 0 6 (6.2%) 0.005 
Table 4. Acute toxicities by common toxicity criteria during the
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of combining radiotherapy with 5-FU as a bolus or CI. The
rates of pathologic complete response have been between 8%
and 33% (1, 15-18). Although the data are limited and there
are no studies comparing bolus versus CI delivery, the efficacy
results, including pathologic complete response, down-stag-
ing, and sphincter preservation, appear to favour CI schemes.
However, the need for indwelling catheters and infusion
pumps imposes limits on this method of administration.
During a 9-yr period, we had consistently employed a treat-
ment policy of concurrent preoperative chemoradiotherapy
(differing only in chemotherapy regimen: bolus 5-FU/LV vs.
oral capecitabine/LV) for patients with LARC. As the pre-
treatment characteristics of the patients in the two groups
were nearly comparable, we retrospectively compared acute
toxicities during preoperative chemoradiotherapy, the patho-
logic responses of the tumors, and sphincter preservation.
Patients treated with CI 5-FU tend to experience lower
overall levels of toxicity than those receiving bolus chemo-
therapy. These differences are especially apparent for hema-
tologic toxicities (19). The main toxicities of bolus 5-FU in-
jection are oral mucositis, gastrointestinal toxicity (diarrhea),
myelosuppression, and skin toxicity. In a randomised phase
III trial, capecitabine was less toxic than bolus 5-FU/LV when
administered to patients with advanced colorectal cancer (20).
Oral capecitabine treatment results in a significantly lower
incidence of myelosuppression, diarrhea, stomatitis, nausea,
and alopecia than bolus 5-FU/LV treatment. Grade 3 hand-
foot syndrome developed more frequently after oral capecita-
bine treatment than after bolus 5-FU/LV treatment. In pa-
tients receiving high-dose CI 5-FU/LV, hand-foot syndrome
was a frequent side effect, but it did not significantly affect
the patients’ quality of life or the delivery of the planned chemo-
therapy (21). In this study, grade 3/4 leucopoenia and throm-
bocytopenia occurred only in the bolus 5-FU/LV group, with
no incidences of these toxicities in the oral capecitabine/LV
group. The most commonly occurring grade 3 non-hemato-
logic toxicities were diarrhea and radiation dermatitis in the
bolus 5-FU/LV treatment group, and diarrhea and hand-foot
syndrome in the oral capecitabine/LV group. Statistically, there
was less diarrhea and radiation dermatitis in the latter group,
although hand-foot syndrome occurred more frequently. As
the tumors in Group I patients were located slightly nearer
to the anal verge than those in Group II patients, this would
have contributed, to some extent, to the clinically significant
radiation dermatitis in Group I, especially because a perineal
reaction to radiation therapy would be severe in patients with
distal rectal tumors. Most patients with symptomatic hand-
foot syndrome in the oral capecitabine/LV group could be easi-
ly managed with vitamin B6 administration and supportive
care without interrupting the radiotherapy schedule.
Tumor down-staging induced by preoperative chemoradio-
therapy is closely related to pathologic complete response and
sphincter preservation in patients with distal rectal cancer.
Janjan et al. examined the rates of tumor down-staging and
sphincter preservation after CI 5-FU in 117 patients with
LARC (16). The patients received radiotherapy of 45 Gy over
5 weeks concurrent with CI 5-FU (300 mg/m
2/day). The rate
of tumor down-staging was 62%, and the rate of pathologic
complete response was 27%. Crane et al. also reported that,
in clinical T3/4 rectal cancers, the addition of CI 5-FU to pre-
operative radiotherapy increased tumor down-staging (62 vs.
42%), pathologic complete response (23 vs. 5%), and sphinc-
ter preservation (39 vs. 13%) in the subset of patients who
had tumors within 6 cm of the anal verge (17). Our results
of tumor down-staging and pathologic response in the oral
capecitabine/LV group are compatible to these findings. The
higher down-staging rate of primary tumors in oral capecita-
bine group than in LV group may explain the higher sphinc-
ter-preservation rate in patients with distal rectal tumors in
our study. However, favourable effects, including tumor down-
staging and sphincter preservation, found in the oral capecita-
bine group may have been affected by several factors, such as
an inherent weakness in the retrospective study, a difference
in the tumor distance from the anal verge, or pre-treatment
clinical TNM staging made without endorectal ultrasound
or MRI. A pathologic response following preoperative chemo-
radiotherapy of patients with LARC can be regarded as a sig-
nificant prognostic indicator for long-term survival. Mohiud-
din et al. reported that the degree of down-staging (postoper-
ative pathologic stage) was closely related to long-term sur-
vival (100% for pT0-2N0, 80% for pT3-4N0, and 73% for
pTxN1-2) (15). This suggests that a higher pathologic res-
ponse, induced by an effective preoperative chemoradiother-
apy, can be translated into a better survival outcome of pa-
tients with LARC. 
Although there are few randomised studies comparing
bolus 5-FU with CI 5-FU in the preoperative radiotherapy
of rectal cancer, we can postulate that CI 5-FU is superior to
bolus 5-FU in terms of tumor response based on other stud-
ies of advanced colorectal cancer (7). As oral capecitabine mi-
mics CI 5-FU in its pharmacologic action in vivo, it is not
surprising that patients treated with oral capecitabine/LV had
higher rates of tumor down-staging, pathologic complete res-
ponse, and sphincter preservation than did patients treated
with bolus 5-FU/LV in this study.
In summary, our results suggest that preoperative chemora-
diation with oral capecitabine/LV is more tolerable with res-
pect to side effects and offers a more effective treatment mo-
dality than bolus 5-FU/LV, as measured by tumor down-stag-
ing, pathologic response, and sphincter preservation.
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